DUBLIN--(BUSINESS WIRE)--The "Epilepsy - Market Insights, Epidemiology and Market Forecasts to 2027" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Epilepsy in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
Epilepsy market is expected to grow during the forecasted period of 2018-2027 owing to the launch of nine drugs (presently in Phase III). Epilepsy Therapeutics market has seen a global sales of 5.4 billion in 2016. The three best selling drugs were Vimpat (UCB), Lamictal (Glaxosmithkline) and Keppra (UCB) with Vimpat recording highest sales of 895 million in 2016.
According to research, the prevalent cases of Epilepsy was 7,649,695 in 2016 in 7MM. Among 7MM, United States account for highest prevalent cases of Epilepsy with 4,007,026 prevalent cases in 2016 followed by Germany.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Epilepsy from 2016 to 2027 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Companies Mentioned
- Catalyst Pharmaceuticals
- GW Pharmaceuticals
- Marinus Pharmaceuticals
- Pfizer
- Sage Therapeutics
- UCB
- Ultragenyx Pharmaceutical
- Zogenix
- Zynerba Pharma
Key Topics Covered:
1. Report Summary
2. Epilepsy Disease Background
3. Epidemiology and Patient Population
4. Treatment Algorithm
5. Unmet Needs
6. Competitive Landscape - Marketed Drugs
7. Emerging Therapies
8. Market Size of Epilepsy
9. Global Market Size
10. United States
11. EU5
12. Japan
13. Market Drivers
14. Market Barriers
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/7h4lmz/global_epilepsy?w=4
